Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

721
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
721
Positron Emission Tomography01:29

Positron Emission Tomography

8.0K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.

Clinical lymphoma, myeloma & leukemia·2014
Same author

Activation of a novel c-Myc-miR27-prohibitin 1 circuitry in cholestatic liver injury inhibits glutathione synthesis in mice.

Antioxidants & redox signaling·2014
Same author

[Development of Neglect Evaluation Scale for primary school students aged 6-11 years old in rural areas of China].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2014
Same author

A novel transgenic mouse model of Chinese Charcot-Marie-Tooth disease type 2L.

Neural regeneration research·2014
Same author

Recombinant adenovirus-mediated overexpression of 3β-hydroxysteroid-Δ24 reductase.

Neural regeneration research·2014
Same author

Development and characterization of microsatellite markers for Melastoma dodecandrum (Melastomataceae).

Applications in plant sciences·2014

Related Experiment Video

Updated: Mar 19, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

Peptide-based imaging agents for cancer detection.

Xiaolian Sun1, Yesen Li1, Ting Liu1

  • 1Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen 361102, China.

Advanced Drug Delivery Reviews
|June 22, 2016
PubMed
Summary
This summary is machine-generated.

Peptide-based imaging agents offer precise tumor targeting and rapid clearance. Advances in chemical modification enhance their stability, pharmacokinetics, and diagnostic accuracy for clinical use.

Keywords:
Chemical modificationClinical experienceMolecular imagingPeptide

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.0K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.3K

Related Experiment Videos

Last Updated: Mar 19, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.0K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.3K

Area of Science:

  • Biomedical imaging
  • Radiochemistry
  • Molecular imaging

Background:

  • Peptide-based agents target tumor cells overexpressing specific receptors.
  • Chemical modifications improve metabolic stability, pharmacokinetics, and biosafety.
  • Radiolabeled peptides show high diagnostic accuracy and sensitivity in clinical settings.

Purpose of the Study:

  • To review the development of peptide-based imaging agents.
  • To emphasize probe design considerations for clinical translation.
  • To provide examples of agents in clinical trials and their diagnostic capabilities.

Main Methods:

  • Review of current literature on peptide-based imaging agents.
  • Analysis of probe design strategies, including peptide selection and chemical modification.
  • Comparison of diagnostic capabilities of agents in clinical trials with FDA-approved agents.

Main Results:

  • Peptide-based agents demonstrate unique properties like rapid clearance and high target specificity.
  • Chemical modifications enhance imaging agent performance and biosafety.
  • Several radiolabeled peptides have achieved clinical translation with notable diagnostic accuracy.

Conclusions:

  • Peptide-based imaging agents are promising tools for molecular imaging of cancer.
  • Careful probe design, including peptide selection and modification, is crucial for clinical success.
  • Ongoing clinical trials highlight the diagnostic potential of these agents compared to existing methods.